<DOC>
	<DOCNO>NCT00034788</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety REGRANEXÂ® Gel compare placebo apply 52 consecutive week recur non-healing ulcer ankle foot relate diabetes .</brief_summary>
	<brief_title>A Study Efficacy Safety Long-Term Treatment Re-Treatment Lower Extremity Diabetic Ulcers With REGRANEX</brief_title>
	<detailed_description>This study initial open-label treatment period 20 week REGRANEX® gel ulcer ankle foot relate diabetes mellitus . Gel apply day thin layer cover entire surface ulcer ; non-adherent dressing gauze use cover gel . If ulcer heal open-label period , remain healed 24 week observation , patient discontinues study . If one ulcer heal 20 week , ulcer recur new ulcer observe 24 week observation , patient enters Double-blind Phase # 1 neither patient physician know whether study drug placebo apply ulcer . This Phase # 1 may continue 52 week . If one ulcer heal 52 week treatment , patient discontinues study . If ulcer heal phase , remain healed 24 week observation , patient discontinues study . If ulcer recur new ulcer observe observation period follow Phase # 1 treatment , patient enters Double-blind Phase # 2 study 20 week . If ulcer heal Phase # 2 treatment , patient discontinues study time . If ulcer remain unhealed 20 week Phase # 2 , study stop . Efficacy assessment include time complete heal ulcer , incidence complete ulcer healing , reduction total ulcer area end study . Safety assessment include incidence adverse event throughout study , change clinical laboratory test ( hematology , chemistry , urinalysis ) , measurement vital sign specify interval , physical examination start end study . The study hypothesis time complete heal diabetic foot ulcer continue treatment use REGRANEX® short time heal placebo patient well tolerate medication . REGRANEX® gel ( placebo ) apply cover entire surface ulcer , day 52 week</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Skin Ulcer</mesh_term>
	<mesh_term>Platelet-derived growth factor BB</mesh_term>
	<criteria>Diagnosis Type I Type II diabetes mellitus glycohemoglobin A1c &lt; 12 % Minimum one neuropathic , diabetic ulcer meeting follow criterion : stage III IV , locate distal low extremity , 1 15 square centimeter No exposed bone ulcer site No osteomyelitis affect area ulcer unless receive aggressive treatment expectation cure Adequate arterial circulation foot New ulcer must meet following criterion : fullthickness ulcer ( Stage III IV ) , locate foot ankle , expose bone ulcer site , osteomyelitis affect area ulcer unless receive aggressive treatment expectation cure Recurrent ulcer must meet following criterion : stage II , III IV , expose bone ulcer site , osteomyelitis affect area ulcer unless receive aggressive treatment expectation cure Females must postmenopausal , surgically incapable childbearing , use acceptable method birth control negative pregnancy test Hypersensitivity REGRANEX® Gel one component Presence two fullthickness diabetic ulcer either low extremity presence active systemic local cancer tumor kind Use topical antibiotic , antiseptic , enzymatic debriders , agent select ulcer , within seven day precede randomization Active rheumatic collagen vascular disease preexist condition disease may interfere evaluation safety efficacy Regranex Systemic corticosteroid maintenance therapy , immunosuppressive chemotherapeutic agent within 14 day prior first study drug application likely receive one therapy study participation Radiation therapy include distal low extremity , time patient 's life Charcot deformity ( rocker bottom foot )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Regranex</keyword>
	<keyword>Foot ulcer</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Diabetic foot</keyword>
</DOC>